B1

--116. A method for enhancing the bioavailability of a bioactive agent *in vivo* comprising (i) administering said bioactive agent to a patient, (ii) administering a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers to the patient, and (iii) applying ultrasonic energy to the patient in an amount sufficient to produce cavitation of said vesicles, wherein said vesicle composition is administered to said patient at a rate which comprises continuous infusion.

117. A method according to Claim 116 wherein said bioactive agent is administered to said patient at a rate which comprises continuous infusion.

118. A method according to Claim 116 wherein said bioactive agent and said vesicle composition are administered to said patient substantially simultaneously.

119. A method according to Claim 116 further comprising imaging said patient using diagnostic ultrasound imaging.

120. A method according to Claim 116 wherein said vesicles comprise lipids.

121. A method according to Claim 120 wherein said vesicle composition comprises vesicles selected from the group consisting of micelles and liposomes.

122. A method according to Claim 120 wherein said lipids comprise phospholipids.

123. A method according to Claim 122 wherein said phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine and phosphatidic acid.

124. A method according to Claim 123 wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidyl-choline, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

B1 cont

125. A method according to Claim 124 wherein said phosphatidylcholine comprises dipalmitoylphosphatidylcholine.

126. A method according to Claim 123 wherein said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, N-succinyldioleoylphosphatidylethanolamine and 1-hexadecyl-2-palmitoylglycerophosphoethanolamine.

127. A method according to Claim 126 wherein said phosphatidylethanol-amine comprises dipalmitoylphosphatidylethanolamine.

128. A method according to Claim 123 wherein said phosphatidic acid comprises dipalmitolylphosphatidic acid.

129. A method according to Claim 120 wherein said lipid further comprises a polymer.

130. A method according to Claim 129 wherein said polymer comprises a hydrophilic polymer.

131. A method according to Claim 130 wherein said hydrophilic polymer comprises polyethylene glycol.

132. A method according to Claim 116 wherein said vesicles comprise proteins.

133. A method according to Claim 132 wherein said proteins comprise albumin.

134. A method according to Claim 116 wherein said vesicles comprise polymers.

135. A method according to Claim 134 wherein said polymers comprise synthetic polymers or copolymers which are prepared from monomers selected from the group consisting of poly-lactic acid, poly-lactide, poly-lactide co-glycolide, acrylic acid, methacrylic acid, ethyleneimine, crotonic acid, acrylamide, ethyl acrylate, methyl methacrylate, 2-hydroxyethyl

B1 cont

methacrylate, lactic acid, glycolic acid, ε-caprolactone, acrolein, cyanoacrylate, bisphenol A, epichlorhydrin, hydroxyalkylacrylates, siloxane, dimethylsiloxane, ethylene oxide, ethylene glycol, hydroxyalkylmethacrylates, N-substituted acrylamides, N-substituted methacrylamides, N-vinyl-2-pyrrolidone, 2,4-pentadiene-1-ol, vinyl acetate, acrylonitrile, styrene, p-amino-styrene, p-aminobenzylstyrene, sodium styrene sulfonate, sodium 2-sulfoxyethyl-methacrylate, vinyl pyridine, aminoethyl methacrylates and 2-methacryloyloxytrimethyl-ammonium chloride.

136. A method according to Claim 134 wherein said polymers comprise synthetic polymers or copolymers selected from the group consisting of polyacrylic acid, polyethyleneimine, polymethacrylic acid, polymethylmethacrylate, polysiloxane, polydimethylsiloxane, polylactic acid, poly(ε-caprolactone), epoxy resin, poly(ethylene oxide), poly(ethylene glycol), polyamide, polyvinylidene-polyacrylonitrile, polyvinylidene-polyacrylonitrile-polymethylmethacrylate and polystyrene-polyacrylonitrile.

137. A method according to Claim 134 wherein said polymers comprise polyvinylidene-polyacrylonitrile copolymer.

138. A method according to Claim 116 wherein said gas comprises a fluorinated gas.

139. A method according to Claim 138 wherein said fluorinated gas is selected from the group consisting of a perfluorocarbon and sulfur hexafluoride.

140. A method according to Claim 139 wherein said fluorinated gas comprises a perfluorocarbon.

141. A method according to Claim 140 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluorocyclobutane.

B' cont

142. A method according to Claim 116 wherein said gaseous precursor has a boiling point of greater than about 37°C.

143. A method according to Claim 142 wherein said gaseous precursor comprises a fluorinated compound.

144. A method according to Claim 143 wherein said fluorinated compound comprises a perfluorocarbon.

145. A method according to Claim 144 wherein said perfluorocarbon is selected from the group consisting of perfluoropentane and perfluorohexane.

146. A method according to Claim 116 wherein said vesicle composition is administered to the patient at a rate of from about 1×10^6 to less than about 8×10^6 vesicles/Kg-sec.

147. A method according to Claim 146 wherein said vesicle composition is administered at a rate of from about 1×10^6 to about 7×10^6 vesicles/Kg-sec.

148. A method according to Claim 147 wherein said vesicle composition is administered at a rate of from about 1.5×10^6 to about 6×10^6 vesicles/Kg-sec.

149. A method according to Claim 148 wherein said vesicle composition is administered at a rate of from about 2×10^6 to about 5.5×10^6 vesicles/Kg-sec.

150. A method according to Claim 149 wherein said vesicle composition is administered at a rate of from about 2.5×10^6 to about 5×10^6 vesicles/Kg-sec.

151. A method according to Claim 150 wherein said vesicle composition is administered at a rate of from about 3×10^6 to about 4.5×10^6 vesicles/Kg-sec.

B1 cont

152. A method according to Claim 117 wherein said vesicle composition is administered to the patient at a rate of from about 1 x 10^{-7} to about 3 x 10^{-3} cc gas/Kg-sec.

153. A method according to Claim 152 wherein said vesicle composition is administered at a rate of from about 3 x 10^{-6} to about 3 x 10^{-3} cc gas/Kg-sec.

154. A method according to Claim 153 wherein said vesicle composition is administered at a rate of from about 4 x 10^{-6} to about 2 x 10^{-3} cc gas/Kg-sec.

155. A method according to Claim 154 wherein said vesicle composition is administered at a rate of from about 8 x 10^{-6} to about 2 x 10^{-3} cc gas/Kg-sec.

156. A method according to Claim 155 wherein said vesicle composition is administered at a rate of from about 1 x 10^{-5} to about 1 x 10^{-3} cc gas/Kg-sec.

157. A method according to Claim 156 wherein said vesicle composition is administered at a rate of from about 4 x 10^{-5} to about 1 x 10^{-3} cc gas/Kg-sec.

158. A method according to Claim 157 wherein said vesicle composition is administered at a rate of from about 8 x 10^{-5} to less than about 1 x 10^{-3} cc gas/Kg-sec.

159. A method according to Claim 158 wherein said vesicle composition is administered at a rate of from about 1 x 10^{-4} to about 9 x 10^{-4} cc gas/Kg-sec.

160. A method according to Claim 116 wherein said bioactive agent is selected form the group consisting of a diagnostic agent, genetic material, a peptide, a beta-agonist, an anti-asthmatic, a steroid, a cholinergic agent, an anti-cholinergic agent, a 5-lipoxygenase inhibitor, a leukotriene inhibitor, an anti-neoplastic agent, an antibiotic, an anti-tumor drug, a radiation sensitizer, a thrombolytic agent, an anti-histamine, an anti-coagulant, an anti-inflammatory, a hormone, a growth factor, an angiogenic factor and a mitotic inhibitor.

161. A method according to Claim 160 wherein said bioactive agent comprises an anti-neoplastic agent.

162. A method according to Claim 161 wherein said bioactive agent comprises paclitxel.

163. The method of Claim 45 wherein said bioactive agent comprises genetic material selected from the group consisting of a nucleic acid, RNA, DNA, recombinant RNA, recombinant DNA, antisense RNA, antisense DNA, hammerhead RNA, a ribozyme, a hammerhead ribozyme, an antigene nucleic acid, a ribooligonucleotide, a deoxyribooligonucleotide, an antisense ribooligonucleotide, and an antisense deoxyribooligonucleotide.

164. A method of enhancing the delivery of a bioactive agent in tissue *in vivo* comprising (i) administering said bioactive agent to a patient, (ii) administering an acoustically active composition to said patient, and (iii) applying ultrasonic energy to said tissue in an amount sufficient to activate said acoustically active composition, wherein said acoustically active composition is administered to said patient at a rate which comprises continuous infusion.

165. A method according to Claim 164 wherein said bioactive agent is administered to said patient at a rate which comprises continuous infusion.

166. A method according to Claim 164 wherein said bioactive agent and said acoustically active composition are administered to said patient substantially simultaneously.

167. A method according to Claim 164 wherein said tissue comprises neoplastic tissue.

168. A method according to Claim 164 wherein said tissue comprises an area of reduced blood perfusion.

169. A method according to Claim 168 wherein said area of reduced blood perfusion comprises ischemic tissue.

B1 Cont

170. A method according to Claim 164 wherein said tissue comprises myocardium.

171. A method according to Claim 164 wherein said tissue comprises glandular tissue.

172. A method according to Claim 171 wherein said glandular tissue comprises the prostate gland.

173. A method according to Claim 164 further comprising imaging said tissue using diagnostic ultrasound imaging.

174. A method according to Claim 164 wherein said bioactive agent comprises an agent selected form the group consisting of a diagnostic agent, genetic material, a peptide, a beta-agonist, an anti-asthmatic, a steroid, a cholinergic agent, an anti-cholinergic agent, a 5-lipoxygenase inhibitor, a leukotriene inhibitor, an anti-neoplastic agent, an antibiotic, an anti-tumor drug, a radiation sensitizer, a thrombolytic agent, an anti-histamine, an anti-coagulant, an anti-inflammatory, a hormone, a growth factor, an angiogenic factor and a mitotic inhibitor.

175. A method according to Claim 164 wherein said bioactive agent comprises an anti-neoplastic agent.

176. A method according to Claim 175 wherein said bioactive agent comprises paclitaxel.

177. A method according to Claim 173 wherein the bioactive agent comprises genetic material selected from the group consisting of a nucleic acid, RNA, DNA, recombinant RNA, recombinant DNA, antisense RNA, antisense DNA, hammerhead RNA, a ribozyme, a hammerhead ribozyme, an antigene nucleic acid, a ribooligonucleotide, a deoxyribooligonucleotide, an antisense ribooligonucleotide, and an antisense deoxyribooligonucleotide.

178. A method according to Claim 174 wherein said acoustically active composition and bioactive agent are administered prior to said application of ultrasound energy.